Newsfile Corp
04 Jul 2026, 22:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri Trial failed to observe the primary endpoint of a statistically significant reduction in Stage III and IV cancers. — The failure of a primary clinical trial endpoint for a core product typically leads to severe valuation write-downs and loss of investor confidence.
-0.90Grail is facing a federal securities class action lawsuit alleging it misled investors about the likelihood of success and trial design of the NHS-Galleri trial. — Litigation creates legal liabilities and reputational risk, though it is a trailing indicator of the trial failure itself.
-0.40Grail's stock price declined approximately 50.55% in a single day following the disclosure of the trial results on February 19, 2026. — This confirms the market has already priced in the immediate shock of the clinical failure.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a federal securities class action lawsuit following a 50% stock price drop due to the failure of its NHS-Galleri trial to meet its primary endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
